RETENTION RATES OF ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB AS BIOTHERAPIES FOR RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, OR PSORIATIC ARTHRITIS PATIENTS IN DAILY PRACTICE IN AUVERGNE (FRANCE)

被引：0
|
作者：
Soubrier, M. [1 ]
Fan, A. [1 ]
Couderc, M. [1 ]
Malochet-Guinamand, S. [1 ]
Mathieu, S. [1 ]
Giraud, C. [1 ]
Tournadre, A. [1 ]
Dubost, J. -J. [1 ]
Pereira, B. [2 ]
机构：
[1] CHU Clermont Ferrand, Dept Rheumatol, Clermont Ferrand, France
[2] CHU Clermont Ferrand, Biostat Unit, Clermont Ferrand, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.5086
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB1333
引用
收藏
页码：1756 / 1756
页数：1
相关论文
共 50 条
  • [1] RETENTION RATES OF ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB AS FIRST-OR SECOND-LINE BIOTHERAPIES FOR SPONDYLOARTHRITIS PATIENTS IN DAILY PRACTICE IN AUVERGNE (FRANCE)
    Soubrier, M.
    Castagne, B.
    Pereira, B.
    Fan, A.
    Frayssac, T.
    Couderc, M.
    Malochet-Guinamand, S.
    Mathieu, S.
    Tatar, Z.
    Tournadre, A.
    Dubost, J-J.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1297 - 1297
  • [2] Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France)
    Soubrier, Martin
    Pereira, Bruno
    Fan, Angelique
    Frayssac, Thomas
    Couderc, Marion
    Malochet-Guinamand, Sandrine
    Mathieu, Sylvain
    Tatar, Zuzana
    Tournadre, Anne
    Dubost, Jean-Jacques
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2018, 21 (11) : 1986 - 1992
  • [3] Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience
    Soubrier, Martin
    Pereira, Bruno
    Frayssac, Thomas
    Fan, Angelique
    Couderc, Marion
    Malochet-Guinamand, Sandrine
    Mathieu, Sylvain
    Tatar, Zuzana
    Tournadre, Anne
    Dubost, Jean-Jacques
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2018, 21 (11) : 1924 - 1932
  • [4] RETENTION RATES OF ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB AS 1ST-OR 2ND-LINE BIOTHERAPY FOR RHEUMATOID ARTHRITIS PATIENTS IN DAILY PRACTICE IN AUVERGNE
    Soubrier, M.
    Pereira, B.
    Frayssac, T.
    Fan, A.
    Couderc, M.
    Malochet-Guinamand, S.
    Mathieu, S.
    Tatar, Z.
    Tournadre, A.
    Dubost, J. -J.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 813 - 813
  • [5] Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice
    Frazier-Mironer, Aline
    Dougados, Maxime
    Mariette, Xavier
    Cantagrel, Alain
    Deschamps, Veronique
    Flipo, Rene Marc
    Logeart, Isabelle
    Schaeverbeke, Thierry
    Sibilia, Jean
    Le Loet, Xavier
    Combe, Bernard
    JOINT BONE SPINE, 2014, 81 (04) : 352 - 359
  • [6] ETANERCEPT RETENTION RATES IN PATIENTS WITH RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS OR PSORIATIC ARTHRITIS
    Dongen, C. V.
    Kneepkens, E.
    Vogelzang, E.
    l'Ami, M.
    Krieckaert, C.
    van der Horst, I.
    Voskuyl, A.
    Nurmohamed, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 1145 - 1145
  • [7] RETENTION RATES OF ADALIMUMAB, ETANERCEPT AND INFLIXIMAB AS FIRST AND SECOND-LINE BIOLOGIC THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN DAILY PRACTICE: THE MAINTAIN STUDY
    Frazier-Mironer, A.
    Cantagrel, A.
    Combe, B.
    Deschamps, V.
    Dougados, M.
    Flipo, R. -M.
    Logeart, I.
    Mariette, X.
    Schaeverbeke, T.
    Sibilia, J.
    Le Loet, X.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 221 - 222
  • [8] The drug survival of adalimumab compared to etanercept and infliximab in treatment of patients with rheumatoid arthritis in daily clinical practice
    Kievit, W.
    Fransen, J.
    Kupper, H. H.
    Van de Laar, M. A. F. J.
    De Rooij, D. J. R. A.
    De Gendt, C. M.
    Jansen, T. L.
    Ronday, K. H.
    Bruse, H. L. C.
    Moolenburgh, J. D.
    Janson, M.
    Van Oijen, P. C. M.
    Adang, E. M.
    Van Riel, P. L. C. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 325 - 325
  • [9] Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice
    Ramirez-Herraiz, E.
    Escudero-Vilaplana, V.
    Alanon-Plaza, E.
    Trovato-Lopez, N.
    Herranz-Alonso, A.
    Morell-Baladron, A.
    Sanjurjo-Saez, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (04) : 559 - 565
  • [10] Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis
    Dafna D Gladman
    Nature Clinical Practice Rheumatology, 2008, 4 : 510 - 511
12345